National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 4 of 2001)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, serves to provide a framework for the administration of national health policies and services, including the Pharmaceutical Benefits Scheme (PBS). This legislative instrument, F2007B01056, was introduced to address the need for the periodic review and updating of the list of substances covered under the PBS. The problem it aimed to solve was ensuring that the PBS remains efficient and relevant by removing drugs and medicinal preparations that no longer meet the criteria for subsidy or have been superseded by more effective alternatives. The policy objective, as stated in the text, is to reflect current medical evidence and practices by adjusting the scope of the PBS accordingly. The Declaration under Subsection 85 (2AA) of the National Health Act 1953, made by Brett Anthony Lennon as the Assistant Secretary of the Pharmaceutical Benefits Branch and Delegate of the Minister for Health and Aged Care, specifies certain drugs and medicinal preparations that will cease to be covered by Part VII of the Act, effective from 1 May 2001.

Scope and Application

The National Health Act 1953 applies to the regulation of pharmaceutical benefits within Australia, specifically through the Pharmaceutical Benefits Scheme (PBS). This Act encompasses individuals who are eligible for benefits under the PBS, which includes Australian citizens, permanent residents, and temporary visa holders. The Act also applies to entities such as pharmaceutical manufacturers, pharmacies, and healthcare providers who participate in the PBS by supplying or administering drugs and medicinal preparations. The scope of the Act extends to the conduct and transactions related to the supply and reimbursement of these medications. Geographically, the Act applies on a Commonwealth level, regulating the PBS across the entire nation, including all states and territories. The Act includes exclusions for certain medications, as evidenced by the declaration which removes specific drugs and medicinal preparations from the PBS. This declaration was made by the Assistant Secretary, Pharmaceutical Benefits Branch, Department of Health and Aged Care, on advice from the Pharmaceutical Benefits Advisory Committee. The exclusion of certain drugs from the PBS is further refined through subordinate instruments, which may include amendments to the Schedule over time to reflect changes in medical evidence and policy considerations.

Key Provisions

The main operative sections of this legislative instrument are section 2, which specifies that the drugs and medicinal preparations listed in the Schedule cease to be subject to Part VII of the National Health Act 1953 (section 2). This effectively removes these particular drugs and preparations from the Pharmaceutical Benefits Scheme (PBS), meaning they will no longer be subsidised under the scheme for eligible patients. The Schedule lists the specific drugs affected by this change: Enoxacin, Oestradiol and Medroxyprogesterone Acetate, Pancreatin, and Sodium Cellulose Phosphate. This Act imposes obligations on several parties, including the Department of Health and Aged Care, healthcare providers, and patients. The Department of Health and Aged Care, through its delegate, is responsible for making the declaration under subsection 85(2AA) of the National Health Act 1953 and must ensure that the advice of the Pharmaceutical Benefits Advisory Committee has been obtained as required by subsection 85(2AB). Healthcare providers must cease prescribing or supplying the listed drugs and preparations as PBS-subsidised medicines, while patients who previously received these medications under the PBS will need to seek alternative means of payment or coverage for these drugs. Failure to comply with the provisions of this legislative instrument may result in various consequences. For healthcare providers, prescribing or supplying the specified drugs as PBS-subsidised medications post the commencement date could be considered non-compliance and may lead to disciplinary actions or financial penalties. Patients who continue to seek these medications under the PBS may be required to pay the full cost of the drugs, as they are no longer covered by the scheme. While the legislative instrument does not explicitly state penalties, breaches of the National Health Act 1953 can result in civil or criminal penalties, including fines and imprisonment, depending on the nature and severity of the breach.